Kelly L Walton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7481161/publications.pdf Version: 2024-02-01



KELLY L WALTON

#	Article	IF	CITATIONS
1	Targeting TGF-Î ² Mediated SMAD Signaling for the Prevention of Fibrosis. Frontiers in Pharmacology, 2017, 8, 461.	3.5	393
2	Elevated expression of activins promotes muscle wasting and cachexia. FASEB Journal, 2014, 28, 1711-1723.	0.5	163
3	Prodomains regulate the synthesis, extracellular localisation and activity of TGF-Î ² superfamily ligands. Growth Factors, 2011, 29, 174-186.	1.7	99
4	Two Distinct Regions of Latency-associated Peptide Coordinate Stability of the Latent Transforming Growth Factor-β1 Complex. Journal of Biological Chemistry, 2010, 285, 17029-17037.	3.4	96
5	Structural basis for potency differences between GDF8 and GDF11. BMC Biology, 2017, 15, 19.	3.8	90
6	Specific targeting of TGF-Î ² family ligands demonstrates distinct roles in the regulation of muscle mass in health and disease. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E5266-E5275.	7.1	90
7	New insights into the mechanisms of activin action and inhibition. Molecular and Cellular Endocrinology, 2012, 359, 2-12.	3.2	81
8	Hormonal Regulation of Sertoli Cell Micro-RNAs at Spermiation. Endocrinology, 2011, 152, 1670-1683.	2.8	78
9	<i>Smad7</i> gene delivery prevents muscle wasting associated with cancer cachexia in mice. Science Translational Medicine, 2016, 8, 348ra98.	12.4	70
10	The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma. Oncotarget, 2017, 8, 18640-18656.	1.8	66
11	A Common Biosynthetic Pathway Governs the Dimerization and Secretion of Inhibin and Related Transforming Growth Factor β (TGFβ) Ligands. Journal of Biological Chemistry, 2009, 284, 9311-9320.	3.4	63
12	Differential Effects of IL6 and Activin A in the Development of Cancer-Associated Cachexia. Cancer Research, 2016, 76, 5372-5382.	0.9	62
13	Activin Signaling Regulates Sertoli Cell Differentiation and Function. Endocrinology, 2012, 153, 6065-6077.	2.8	61
14	The TGF-β Signalling Network in Muscle Development, Adaptation and Disease. Advances in Experimental Medicine and Biology, 2016, 900, 97-131.	1.6	56
15	Development of Novel Activin-Targeted Therapeutics. Molecular Therapy, 2015, 23, 434-444.	8.2	46
16	Suppression of Inhibin A Biological Activity by Alterations in the Binding Site for Betaglycan. Journal of Biological Chemistry, 2008, 283, 16743-16751.	3.4	42
17	New insights into the genetic basis of premature ovarian insufficiency: Novel causative variants and candidate genes revealed by genomic sequencing. Maturitas, 2020, 141, 9-19.	2.4	41
18	Activation of Latent Human GDF9 by a Single Residue Change (Gly391Arg) in the Mature Domain. Endocrinology, 2012, 153, 1301-1310.	2.8	40

KELLY L WALTON

#	Article	IF	CITATIONS
19	Inhibin B Is a More Potent Suppressor of Rat Follicle-Stimulating Hormone Release than Inhibin A in Vitro and in Vivo. Endocrinology, 2009, 150, 4784-4793.	2.8	38
20	BMP15 Mutations Associated With Primary Ovarian Insufficiency Reduce Expression, Activity, or Synergy With GDF9. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1009-1019.	3.6	31
21	Molecular characterization of latent GDF8 reveals mechanisms of activation. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E866-E875.	7.1	30
22	Species Differences in the Expression and Activity of Bone Morphogenetic Protein 15. Endocrinology, 2013, 154, 888-899.	2.8	28
23	A variant of human growth differentiation factor-9 that improves oocyte developmental competence. Journal of Biological Chemistry, 2020, 295, 7981-7991.	3.4	28
24	HtrA3 as an Early Marker for Preeclampsia: Specific Monoclonal Antibodies and Sensitive High-Throughput Assays for Serum Screening. PLoS ONE, 2012, 7, e45956.	2.5	28
25	Structure of AMH bound to AMHR2 provides insight into a unique signaling pair in the TGF-β family. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	26
26	The Synthesis and Secretion of Inhibins. Vitamins and Hormones, 2011, 85, 149-184.	1.7	23
27	Generation of a Specific Activin Antagonist by Modification of the Activin A Propeptide. Endocrinology, 2011, 152, 3758-3768.	2.8	23
28	TGFBR3L is an inhibin B co-receptor that regulates female fertility. Science Advances, 2021, 7, eabl4391.	10.3	21
29	Serum Concentrations of Oocyte-Secreted Factors BMP15 and GDF9 During IVF and in Women With Reproductive Pathologies. Endocrinology, 2019, 160, 2298-2313.	2.8	19
30	Activin A–Induced Cachectic Wasting Is Attenuated by Systemic Delivery of Its Cognate Propeptide in Male Mice. Endocrinology, 2019, 160, 2417-2426.	2.8	17
31	Cumulin and FSH Cooperate to Regulate Inhibin B and Activin B Production by Human Granulosa-Lutein Cells In Vitro. Endocrinology, 2019, 160, 853-862.	2.8	17
32	Biological activity and inÂvivo half-life of pro-activin A in male rats. Molecular and Cellular Endocrinology, 2016, 422, 84-92.	3.2	14
33	Multiple Soluble TGF-β Receptors in Addition to Soluble Endoglin Are Elevated in Preeclamptic Serum and They Synergistically Inhibit TGF-β Signaling. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3065-3074.	3.6	13
34	Germline Mutations of Inhibins in Earlyâ€Onset Ovarian Epithelial Tumors. Human Mutation, 2014, 35, 294-297.	2.5	11
35	Inhibin Biosynthesis and Activity Are Limited by a Prodomain-Derived Peptide. Endocrinology, 2015, 156, 3047-3057.	2.8	10
36	A Novel, More Efficient Approach to Generate Bioactive Inhibins. Endocrinology, 2016, 157, 2799-2809.	2.8	10

KELLY L WALTON

#	Article	IF	CITATIONS
37	2-Phenyl and 2-heterocyclic-4-(3-(pyridin-2-yl)-1H-pyrazol-4-yl)pyridines as inhibitors of TGF-β1 and activin A signalling. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 5642-5645.	2.2	8
38	Engineering the Ovarian Hormones Inhibin A and Inhibin B to Enhance Synthesis and Activity. Endocrinology, 2020, 161, .	2.8	8
39	Use of detergent-based buffers allows detection of precursor inhibin forms in an immunoassay format. Molecular and Cellular Endocrinology, 2013, 381, 106-114.	3.2	6
40	Development of a high-throughput assay for human proprotein convertase 5/6 for detecting uterine receptivity. Analytical Biochemistry, 2015, 475, 14-21.	2.4	5
41	TMEPAI/PMEPA1 Is a Positive Regulator of Skeletal Muscle Mass. Frontiers in Physiology, 2020, 11, 560225.	2.8	5
42	Inhibin Inactivation in Female Mice Leads to Elevated FSH Levels, Ovarian Overstimulation, and Pregnancy Loss. Endocrinology, 2022, 163, .	2.8	5
43	Identification of protein binding partners of ALK-5 kinase inhibitors. Bioorganic and Medicinal Chemistry, 2013, 21, 6496-6500.	3.0	2
44	Functional Characterization of Two New Variants in the Bone Morphogenetic Protein 7 Prodomain in Two Pairs of Monozygotic Twins With Hypospadias. Journal of the Endocrine Society, 2019, 3, 814-824.	0.2	2
45	Human INHBB Gene Variant (c.1079T>C:p.Met360Thr) Alters Testis Germ Cell Content, but Does Not Impact Fertility in Mice. Endocrinology, 2022, 163, .	2.8	2
46	Inhibin: To Betaglycan, or Not to Betaglycan. Endocrinology, 2019, 160, 341-342.	2.8	1